article

Media Release: 16th December 2021 TGA Rescheduling of Psilocybin and MDMA: Delegate’s Final Decision     On December 15th, the Therapeutic Goods Administration (TGA) announced the [...]

Media Release: 1st of October 2021 TGA Rescheduling of Psilocybin and MDMA Independent Expert Review Panel Report   Yesterday, the Australian Therapeutic Goods Administration (TGA) published [...]

Around the world there is a rapidly growing body of scientific evidence suggesting that psychedelic drugs are safe and highly effective when used under medical supervision. Why did promising [...]

Paul Liknaitzky hopes for “rigorous research that is neither biased toward panacea thinking, nor ignorant of the best-practice track record and literature to date”. “This field has suffered from [...]

Nigel Strauss and Paul Liknaitzky contend that, at least initially, all training should take place within clinical trials overseen by experienced international clinicians and be limited to [...]

While the anecdotal accounts are compelling, significant questions remain around how microdosing works, and how much of the reported benefits are due to pharmacological effects, rather than [...]

People who use drugs understand drugs and drug use in ways that are often different to the way knowledge of drug use is constructed within the dominant medico-legal discourse. Their experiences [...]

There’s a landmark project underway in Melbourne to find out whether psilocybin – the hallucinogenic compound in magic mushrooms – can be used to improve end-of-life [...]

Dr Bright said Australia had the opportunity to “scale up”, with bigger trials ensuring more therapists were trained so when MDMA was given the green light in the US, the safety data [...]

People who use drugs understand drugs and drug use in ways that are often different to the way knowledge of drug use is constructed within the dominant medico-legal discourse. Their experiences [...]

There is increasing evidence that psychedelic-assisted psychotherapy is effective for a range of psychological conditions. There are likely numerous mechanisms of action that contribute to these [...]

…Earlier this year PRISM obtained approval to give psilocybin to 30 terminally ill patients at St Vincent’s Hospital in Melbourne to ease their end-of-life anxiety and crisis. It’s a phase [...]

Psychedelic drugs could revolutionise current treatment options for mental health conditions as growing evidence demonstrates the profound effects of Psilocybin and MDMA. Over 100 studies in the [...]

“After one dose of psilocybin, death anxiety declined…nothing in psychology comes close to that!”, psychiatrist Margaret Ross. St. Vincent’s hospital will undergo novel trials involving [...]

Psychedelics are a broad category of drugs that can produce profound changes in consciousness. “Magic mushrooms”, containing psilocybin, have been used by some indigenous communities for at least [...]

The correlation between mental health conditions and technology suggests that our increased screen time is contributing to poorer overall wellbeing and even addictive symptoms. A new kind of [...]

Psilocybin, the psychoactive compound from magic mushrooms, is being used to treat depression and anxiety in terminally ill patients in a new trial at Melbourne’s St Vincent’s Hospital.

Prestigious international institutions have initiated robust psychedelic research programs. Does Australia risk being left behind if it doesn’t do the same?

New research published in the Australian Psychologist Journal claims Australia is missing out on the benefits of using psychedelic drugs to treat a range of mental health illnesses.

Australia is missing out on a global “renaissance” of research into use of psychedelic drugs to treat mental health problems, two psychologists say.

PRISM President Dr Martin Williams talks with ABC Radio’s Beyond the Lab about the Psychedelic Renaissance.

In a press release dated 26 August 2017, the Multidisciplinary Association for Psychedelic Studies (MAPS) announced that the US Food and Drug Administration has granted ‘Breakthrough [...]

Scientists believe the illegal drug MDMA, also known as ecstasy, has an untapped potential to treat post-traumatic stress disorder (PTSD). But they say plans to test the drug on war veterans in [...]

PRISM is a proud sponsor of the Entheogenesis Australis 2017 Outdoor Psychedelic Symposium. For over a decade Entheogenesis Australis has provided a major meeting place for ethnobotanical [...]

PRISM Vice President Dr Stephen Bright reflects on his attendance as a guest speaker at Beyond Psychedelics 2016 in Prague.

Dr Stephen Bright talks to The Psychedelia Podcast about the problems facing the psychedelic movement in Australia